1 drop in each eye BID, continued throughout allergen exposure
Itch relief begins within 3 minutes and lasts at least 8 hours.
OFF-LABELNot in the FDA label for this product
Seasonal allergic conjunctivitis in soft contact lens wearers with shortened comfortable wear time
1 drop BID plus rewetting drops as needed, the regimen used in the trial
Open-label RCT · n=146
Randomized, open-label, multicenter trial during allergy season (N=146, 75 treated vs 71 on rewetting drops alone): mean comfortable wearing time rose 1.33 h vs 0.43 h (P=0.012) and total wearing time 0.35 h vs -0.32 h (P=0.008), with greater improvement in itch and overall comfort and fewer rewetting drop instillations. Read alongside the label, which states the product is not for contact lens-related irritation and that lenses come out before instillation.
Ophthalmic solution, 5 mL fill in 10 mL bottle, 0.05% (0.5 mg/mL)
Mechanism of Action
Topically active direct H1-receptor antagonist and inhibitor of histamine release from the mast cell, giving immediate receptor blockade plus mast cell stabilization. Selective for H1, with additional affinity for H2, alpha-1, alpha-2, and 5-HT2 receptors.
Warnings & Precautions
Contact lens wear: Lenses out before instillation; the benzalkonium chloride preservative is absorbed by soft lenses. Reinsertion permitted 10 minutes after dosing.
Contact lens-related irritation: Not indicated for it, and lenses should not be worn on a red eye.
Tip contamination: Dropper contact with the eye, periocular tissue, fingers, or any surface can seed the solution with bacteria; contaminated solutions may cause serious ocular damage and vision loss.
Route restriction: Topical ophthalmic use only; not for injection or oral use.
Common Side Effects
Ocular: Burning sensation, folliculosis, hyperemia, pruritus; approximately 1% to 10%.
Systemic: Cold symptoms and upper respiratory infection, approximately 10%; headache, rhinitis, sinusitis, increased cough, pharyngitis, approximately 1% to 3%.
Postmarketing: Increased lacrimation.
Pregnancy & Lactation
Pregnancy: No adequate and well-controlled studies in pregnant women. Animal data show no drug-induced teratogenic effects, but total resorptions and abortion occurred in rabbits at an oral dose approximately 55,000 times the maximum recommended ocular human dose (MROHD), and reduced pup weight gain in rats at approximately 90,000 times the MROHD.
Lactation: Excreted in the milk of lactating rats; excretion in human milk is unknown.
Pediatric Use
Safety and effectiveness below age 2 not established.
Available Forms
Mechanism of Action
Pregnancy & Lactation
Pediatric Use